Comparative Efficacy of Peptides vs. Traditional Anabolics

Which Is Better Depends on the Goal

Lifters ask all the time whether peptides or steroids are "better." The answer depends on the goal. Traditional anabolic-androgenic steroids (AAS) and the peptides we discuss here don't really compete. They target different biological systems, and no trial has compared them directly.

AAS force body-wide growth through the androgen receptor. Most peptides nudge specific physiological pathways, and the human evidence for what that achieves is much thinner. This page compares them goal by goal. For side-effect profiles in more depth, see our comparison of peptides and anabolic steroids.

Brute Force: The Anabolic Power of AAS

For adding muscle and strength quickly, traditional anabolics have far more human evidence than any peptide. Testosterone and related steroids like nandrolone work mainly by binding to and activating the androgen receptor (AR).

The activated AR moves to the cell nucleus and directly starts transcription of genes related to muscle protein synthesis. It also increases nitrogen retention. In a 1996 trial of 43 healthy men, 600 mg of testosterone enanthate weekly for 10 weeks (a supraphysiologic dose) plus strength training added about 6.1 kg of fat-free mass and about 38 kg to the squat.

But that effect comes with a well-documented cost. Strong, body-wide AR activation leads to HPTA shutdown and lipid disruption, and aromatization can cause gynecomastia and water retention. A 2014 Endocrine Society statement links non-medical steroid use to cardiovascular and psychiatric harm and to a higher risk of death.

Surgical Strike: The Peptide Playbook

Peptides work differently. Most of the peptides used for physique enhancement don't touch the androgen receptor. Instead, they act as signaling molecules, binding to specific receptors to start a cascade of downstream effects in the body's own hormone systems.

The classic example is the growth hormone secretagogue (GHS) stack of CJC-1295 and ipamorelin. CJC-1295 is a GHRH (Growth Hormone Releasing Hormone) analog, and ipamorelin is a ghrelin receptor agonist. Users combine them expecting a larger pulse of the body's own growth hormone, though no controlled human trial has tested the pair. In 2006 studies in healthy adults, one dose of CJC-1295 raised GH 2- to 10-fold for six days or more.

Raising GH isn't the same as losing fat. GH does stimulate lipolysis (the breakdown of fat from fat cells), but human trials haven't shown a fat-loss benefit. FDA's 2024 reviews found no articles on CJC-1295's effectiveness in humans, and a Phase 2 trial of intravenous ipamorelin after bowel surgery failed. The longest trial in the class gave the oral secretagogue MK-677 (not a peptide) to 65 healthy older adults. Over a year they gained about 1 kg of fat-free mass with no change in total fat or strength, while fasting glucose rose.

Our evidence rating for ipamorelin is moderate. Users who report fat loss and better sleep usually have no control group and are also dieting. More detail is in our pages on ipamorelin's role in fat-loss protocols and CJC-1295 for fat loss.

Apples, Oranges, and Physique Goals

Seeing the mechanisms side by side makes the distinction clear. One is not a replacement for the other.

As of October 2026, FDA's 2026 warning letters to peptide sellers say a "research use only" label doesn't protect a seller that makes drug claims or sells bacteriostatic water for reconstitution. In July 2026, the owner of Paradigm Peptides was sentenced to 70 months in prison for selling unapproved drugs, according to CBS News. WADA's 2026 Prohibited List bans BPC-157 (S0), TB-500 (S2.3), GH secretagogues (S2.2.4) and AOD-9604 (S2.2.3) at all times; steroids fall under S1.1. More is in our guide to whether peptides are legal.

The Gray Area: 'Anabolic' Peptides like IGF-1

Now, some peptides do blur the lines: IGF-1 (Insulin-like Growth Factor 1) analogs like IGF-1 LR3, and MGF (Mechano Growth Factor). These aren't GHS; they are downstream effectors of GH and of mechanical tension on the muscle.

Animal and cell studies suggest that after training, muscle releases MGF locally, which signals satellite cells to activate. GH and androgens both drive IGF-1 production, which promotes the fusion of these satellite cells into existing fibers (hypertrophy). In transgenic mice, extra IGF-1 in muscle produced larger fibers. The idea that IGF-1 also forms new fibers (hyperplasia) comes from animal work and hasn't been shown in people.

Injecting IGF-1 LR3 or PEG-MGF is an attempt to shortcut this process and force that local growth signal. Whether it works in humans is unknown: as of October 2026 no human administration studies of IGF-1 LR3 have been published, and our evidence rating for it is preliminary. Low blood sugar is the risk users report most. Bodybuilders often use these peptides alongside AAS, believing they add to steroid-driven growth, a community practice no trial has tested.

Putting It Together: Strategy Over Strength

The better question is what you're trying to achieve right now. The patterns below describe what users do, set against the evidence. They aren't recommendations.

• Goal: Add 20 pounds to my frame in 16 weeks. This is what AAS cycles are used for, and trials back a large effect on muscle mass, with the risks above. No peptide has produced that kind of mass in a trial.
• Goal: Break a fat-loss plateau while preserving muscle. Users most often reach for a CJC-1295/ipamorelin stack here, and many report leaner results. No human trial has shown that GH secretagogues reduce fat. For other options, see how peptides compare with other fat-loss methods.
• Goal: Heal a nagging tendon injury while staying in shape. Many lifters choose BPC-157. A 2025 systematic review found that 35 of 36 studies were preclinical and found no clinical safety data; our evidence rating is emerging. We found no tendon-healing trials of AAS or GH secretagogues either.

AAS have strong human data for muscle and strength, along with well-documented harms. GH-releasing peptides have human data on hormone levels, but not yet on the outcomes lifters use them for.

Comparison table